A compilation of headlines and stories around DARPA and Pentagon Funding of Moderna & Pfizer & other relevant stories. Covid-19 vaccinations have been coordinated with military participation from funding to testing, guarding to distribution. Below, must read stories around the current Covid-19 funding and research over the past decade.
Military Announces funding of vaccine & mRNA projects for Pfizer & Moderna within a three month period in December 2013:
December 8, 2013
News of the project emerged after the Defense Advanced Research Projects Agency (DARPA)--the research arm of the Pentagon--awarded Pfizer a three-year, $7.7 million contract. Details of the research are scarce, but what DARPA has revealed implies it wants to cut response times to pandemic or bioterrorism threats by eliminating several of the steps currently needed to confer immunity.
"Pfizer shall perform a research and development program designed to develop a technology platform to identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual," the Department of Defense wrote in its roundup of recent contracts.
Identifying the antigen and inducing antibody production in vivo would eliminate some of the time-consuming steps currently essential to developing, manufacturing and administering a vaccine. While the project is clearly at a very early stage--and the budget small by biopharma standards--the potential implications of the work are big and far-reaching. Success would overturn traditional vaccine processes.
Pursuit of the technology is a reflection of military concerns about bioterrorism. In October, experts told Congress defense against bioweapons is a "significant national vulnerability," Marine Corps Times reports.
October 8, 2013:;
DARPA Awards Moderna Therapeutics a Grant for up to $25 Million to Develop Messenger RNA Therapeutics™
CAMBRIDGE, Mass., October 2, 2013—Moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.
Messenger RNA therapeutics™ can be designed to tap directly into the body’s natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, Moderna’s messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies.
Merck & Moderna Announced 100 million Dollar Partnership in December 15, 2015 to develop vaccines for FOUR UNDISCLOSED VIRUSES:
January 13, 2015:
Merck & Co. will partner with Moderna Therapeutics to develop antiviral vaccines and passive immunity therapies based on Moderna’s modified messenger-RNA (mRNA) technology. The deal could generate up to $100 million-plus for Moderna, and raises the company’s haul from partners and investors in the new year to more than a half-billion dollars.
The three-year research collaboration with Merck includes the possibility of a one-year extension.
The partnership will focus on the development of five product candidates—new mRNA-based treatments and vaccines—against four undisclosed viruses.
Merck will lead the discovery and development of candidates and commercialization of any products resulting from this license and collaboration agreement. Merck has agreed to pay $50 million upfront toward licenses to access Moderna’s technology, and will make a $50 million equity investment in the biotech. Moderna will be eligible for undisclosed per-product development and commercial milestones under the license as well as tiered royalties on commercial sales.
Moderna Hit the Wall in 2017 with mRNA Technology Due to Safety Issues. Article in Stat magazine stated the company needed a 'Hail Mary' to bypass safety issues which impeded development and release of mRNA technology drugs:
In need of a Hail Mary
"Founded in 2012, Moderna reached unicorn status — a $1 billion valuation — in just two years, faster than Uber, Dropbox, and Lyft, according to CB Insights. The company’s premise: Using custom-built strands of messenger RNA, known as mRNA, it aims to turn the body’s cells into ad hoc drug factories, compelling them to produce the proteins needed to treat a wide variety of diseases.
But mRNA is a tricky technology. Several major pharmaceutical companies have tried and abandoned the idea, struggling to get mRNA into cells without triggering nasty side effects.
Bancel has repeatedly promised that Moderna’s new therapies will change the world, but the company has refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists and a chiding from the editors of Nature.
The indefinite delay on the Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be delivered in multiple doses, covering almost everything that isn’t a vaccine, former employees and collaborators said"
The hail Mary came in 2020 when the FDA granted 'emergency, investigative use only permission' for Moderna's mRNA Covid-19 vaccination allowing the company to entirely bypass the safety issues impeding its release for a virus attribute with a near 100% survival rate in most population groups and 86% asymptomatic presentation rate. The media does not inform the public that regular safety trials were demonstrating the technology unsafe for release.
"Moderna COVID‑19 Vaccine is for use for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The vaccine contains a nucleoside-modified messenger RNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 formulated in lipid particles. It is an investigational vaccine not licensed for any indication (direct quote from FDA permissions letter)".
Fauci Announced a 'Surprise Outbreak' Coming for Next Presidential Administration in 2017:
Gene Line Editing Placed On US Intelligence Lists of Potential Weapons of Mass Destruction:
Military Ranked Gene Link Editing Technology (Crispr technology) employed in Pfizer and Moderna vaccinations as a significant bioweapons threat. Ethics and potential dangers of use of gene line editing have been almost entirely skipped over in the media discussion of use of emergency use, investigative use permission gene line editing drugs. Yet again, technology outpaces our ability to objectively review and fully analyze the risks. Many American remain unaware not only of the methods in which gene line editing Covid-19 drugs actually work; they are also unaware of the military foundations of their development and the serious ethical dilemmas with their use:
June 19, 2018
"The report, issued by the National Academies of Sciences, is among the first to try to rank national security threats made possible by recent advances in gene engineering such as the gene-editing technology CRISPR.
“Synthetic biology does expand the risk. That is not a good-news story,” says Gigi Gronvall, a public health researcher at Johns Hopkins and one of the report’s 13 authors.
“This report provides a framework to systematically evaluate the threat of misuse.”
Experts are divided on the perils posed by synthetic biology, a term used to describe a wide set of techniques for speeding genetic engineering. In 2016, the US intelligence community placed gene editing on its list of potential weapons of mass destruction".
December 4, 2017
"Technology could be used to wipe out malaria carrying mosquitos or other pests but UN experts say fears over possible military uses and unintended consequences strengthen case for a ban"
"The UN Convention on Biological Diversity (CBD) is debating whether to impose a moratorium on the gene research next year and several southern countries fear a possible military application.
UN diplomats confirmed that the new email release would worsen the “bad name” of gene drives in some circles. “Many countries [will] have concerns when this technology comes from Darpa, a US military science agency,” one said.
The use of genetic extinction technologies in bioweapons is the stuff of nightmares, but known research is focused entirely on pest control and eradication".
Got that? Only three years ago, the UN was debating BANNING gene research due to fears of military application, in 2020, untested Covid-19 gene line editing drugs were released on a global scale with NO mid or long term testing under the guise of 'vaccination'. Gene line editing drugs are NOT vaccinations, they act to rewrite the RNA code to train the immune system in a different way. This new technology has no mid or long term studies to ascertain safety or determination of effects on altering the immune system at a genetic level. All reassurance that these drugs are safe is based on LACK of evidence, a unethical and unscientific standard for safety determination of medical therapies.
The inventor of Crispr called for a pause to review ethical considerations in 2015:
The discussion in Napa early this year included Nobel Laureate David Baltimore, who was involved in a similar discussion 40 years ago about the dangers of the then-new recombinant DNA technology, which spawned the genetic engineering revolution.
But while the advent of genetic engineering ushered in a host of new therapeutic drugs and GMO crops, it was a laborious and time-consuming tool. CRISPR-Cas9 is quick and precise, and has already been adopted by thousands of labs around the world.
“The pace of scientific research has really increased with the CRISPR-Cas9 technology,” said Doudna, a UC Berkeley professor of molecular and cell biology and of chemistry and a Howard Hughes Medical Institute investigator. “It is widely available and relatively simple to employ, and it just lowers the barrier for people to start doing experiments that in the past would have been so difficult to do that there was no reason to discuss regulating them – they were just not very practical.”
The speed of change makes a discussion of the ethical and societal issues of editing heritable genes urgent, she said.
The public has never engaged in a real discussion about the ethical implications & dangers of the new gene line editing technology which has now been unleashed on a mass scale through Covid-19 vaccinations. Worse, most citizens, due to the complete lack of responsibility by health professionals and media to independently & objectively review available data, remain unaware a discussion is even necessary.
Biotech, Bayer (Formerly Monsanto) Partner on Gene-Editing Treatments, Bayer Patents Crispr Technology:
21 December 2015. CRISPR Therapeutics and the drug company Bayer AG are forming a joint venture to develop gene-editing therapies for three types of genetic diseases, and later for other human and agricultural applications. The deal calls for Bayer AG, in Leverkusen, Germany, to invest at least $300 million in the joint venture and take an ownership stake in CRISPR Therapeutics, a start-up biotechnology enterprise in Cambridge, Massachusetts and Basel, Switzerland.
CRISPR, short for clustered, regularly interspaced short palindromic repeats, makes it possible to edit genomes of organisms harnessing bacterial defense mechanisms that use RNA to identify and monitor precise locations in DNA.
CRISPR Therapeutics, founded in April 2014, is developing treatments for genetic disorders, where disease-causing mutations are inherited from one or both parents. The company was founded by Emmanuelle Charpentier, a professor at the Helmholtz Centre for Infection Research in Braunschweig, Germany. Charpentier led teams that published pioneering research on gene editing in the journal Science in 2012, and an article in Nature a year earlier. Four other genetics researchers co-founded the company, including Craig Mello, a 2006 Nobel laureate at University of Massachusetts Medical School.
There has been a battle among the world's top wealth to who will own the patents and control Crispr technology:
February 15, 2017
The U.S. Patent Trial and Appeal Board ruled today in favor of the Broad Institute in the high stakes battle over who will control the valuable intellectual property linked to CRISPR, the powerful genome-editing tool. The ruling came after the feature below, from the 16 February issue of Science, was prepared. The decision may be appealed by the University of California, however, and many other CRISPR-related patent applications have been filed by the companies and scientists trying to commercialize its discovery, so the business battle will no doubt continue.
"CoV spike (S) proteins mediate cellular attachment and membrane fusion and are therefore the target of protective antibodies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have developed a novel CoV S protein vaccine antigen. This Start Printed Page 16377technology employs protein engineering to stabilize S in its prefusion conformation, preventing structural rearrangement, and exposing antigenically preferable surfaces. The technology has been applied to several CoV spikes, including those from human-relevant viruses, such as HKU1-CoV, SARS-CoV, and MERS-CoV. Particularly for MERS-COV, stabilized S proteins have been shown to elicit superior neutralizing antibody responses up to 10-fold higher in animal models and protect mice against lethal MERS-CoV infection. This technology is applicable for delivery via other platforms, such as mRNA.
This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration".
Bill & Melinda Gates Foundation Also Funded Gene Drives
In sum, 100s of millions of dollars have been invested in mRNA gene line editing technology that could not meet regular safety trial standards for release under traditional FDA review standards. Over the past decade, the US government & pharmaceutical companies have been working on mRNA drug therapies with anticipation of hundreds of billions in profits per company press releases. Emergency Use approval for Covid-19 vaccinations allowed the government and corporations to bypass trials, on the premise that investigative technology was required to save the population from Covid-19 attributed threat that CDC and WHO documentation show is no worse than any other seasonal flu virus with a very low symptom presentation rate.
For our health....
Please email and share posts, as Unite4Truth remains under severe censorship. Thanks for all you do!